Patent intelligence · PH
PH 12013502690
ANTIBODIES TO ADP-RIBOSYL CYCLASE 2
ANTIBODIES TO ADP-RIBOSYL CYCLASE 2
Patent details — PH 12013502690
- Jurisdiction
- PH
- Status
- granted
- Grant date
- Feb 17, 2014
- Expiration
- Feb 12, 2034
- Applicant
- BERLIN CHEMIE AG [DE]
- CPC classes
- A61K/476871, A61P/100, A61P/104, A61P/1106
Quick answer
PH 12013502690 (ANTIBODIES TO ADP-RIBOSYL CYCLASE 2) is held by BERLIN CHEMIE AG [DE]. Status: granted. Granted Feb 17, 2014. Expires Feb 12, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BERLIN CHEMIE AG [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K/476871, A61P/100, A61P/104, A61P/1106, A61P/1312, A61P/1706
More from BERLIN CHEMIE AG [DE]
Related pharmaceutical patents in our USPTO index.
-
WO 2024252263
COMPOSITIONS SOLIDES DE DICHLORHYDRATE D'ÉLACESTRANT, LEURS PROCÉDÉS DE FABRICATION ET MÉTHODES DE TRAITEMENT LES UTILISANT
granted -
WO 2024023766
POLYTHÉRAPIE À BASE D'INHIBITEUR DE P13K
granted -
CA 3259243
POLYTHÉRAPIE ANTICANCÉREUSE COMPRENANT UN INHIBITEUR DE BCL-2
granted -
CA 3259252
POLYTHÉRAPIE ANTICANCÉREUSE COMPRENANT UN INHIBITEUR DE FLT3
granted -
WO 2022029639
FORMULATIONS PHARMACEUTIQUES AMÉLIORÉES COMPRENANT DES INHIBITEURS DE PI3K
granted -
US 2021015826
ANTICANCER PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY
granted -
US 2020040086
PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-LY75 ANTIBODY
granted -
CA 3102476
ASSOCIATIONS PHARMACEUTIQUES
granted
Frequently asked questions
What is US patent 12013502690?
PH 12013502690 (ANTIBODIES TO ADP-RIBOSYL CYCLASE 2) is held by BERLIN CHEMIE AG [DE]. Status: granted. Granted Feb 17, 2014. Expires Feb 12, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns PH 12013502690?
BERLIN CHEMIE AG [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does PH 12013502690 expire?
Our index shows an expiration date of Feb 12, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.